Back to News
Market Impact: 0.3
SAB Bio Wins FDA Fast Track Status For SAB-142 In Type 1 Diabetes; Stock Up
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
The U.S. FDA granted Fast Track designation to SAB Biotherapeutics’ SAB-142 for treating patients with Stage 3 Type 1 Diabetes. The designation is intended to facilitate development and review; the article excerpt provides no trial results or approval decision.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
SABS0.60
More News
- US fines Bank of America $1.2bn for money laundering, sanctions violations
- Bank of America hit with more than $1.2 billion in penalties over money-laundering violations
- Why is Bank of America stock sliding today?
- More Republicans come out against Trump's diesel deal with Putin
- BofA fined $1.2 billion by US government for failing to police suspicious activity
- J&J's 6% slide on an imperfect quarter is a gift to prospective buyers